Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Chronic Immune Activation in HIV
NCT01866826Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in human immunodeficiency virus infection (HIV), sponsored by National Cancer Institute. Started Jan 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01866826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866826.